Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients
10.1186/s12882-016-0256-0
Saved in:
Main Authors: | Nguyen H.V., Bose S., Finkelstein E. |
---|---|
Other Authors: | DUKE-NUS MEDICAL SCHOOL |
Format: | Article |
Published: |
BioMed Central Ltd.
2018
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/143488 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Protein-bound Uremic Toxins Lowering Effect of Sevelamer in Pre-dialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized Controlled Trial
by: Kullaya Takkavatakarn
Published: (2020) -
Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations
by: Kamolpat Chaiyakittisopon, et al.
Published: (2022) -
Impact of Serum Bicarbonate Levels on Muscle Mass and Kidney Function in Pre-Dialysis Chronic Kidney Disease Patients
by: Piyawan Kittiskulnam, et al.
Published: (2020) -
Investigation of total antioxidant status and antioxidant activity in pre-dialysis chronic kidney disease patients
by: Thi Hoang Lan Bui
Published: (2015) -
Treatment-related decisional conflict in pre-dialysis chronic kidney disease patients in Singapore: prevalence and determinants
by: Goh, Zack Zhong Sheng, et al.
Published: (2022)